{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-064700","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.338174+00:00","generated_at":"2026-06-01T08:49:01.113446+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Dyne Therapeutics shareholders elect three Class I directors, ratify Deloitte as auditor","bullets":["Carlo Incerti, M.D. elected with 61,028,245 votes for, 8,752,856 withheld, 5,235,919 broker non-votes.","Catherine Stehman-Breen, M.D. elected with 55,026,485 votes for, 14,325,362 withheld, 5,665,173 broker non-votes.","John G. Cox elected with 69,763,860 votes for, 32,767 withheld, 5,220,393 broker non-votes.","Ratification of Deloitte & Touche as independent auditor for FY2024 passed with 74,962,217 for, 12,377 against, 42,426 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-064700","json":"https://secwatch.observer/filing/0000950170-24-064700.json","markdown":"https://secwatch.observer/filing/0000950170-24-064700.md","text":"https://secwatch.observer/filing/0000950170-24-064700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024064700/0000950170-24-064700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024064700/dyn-20240522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:49:01.113446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}